InsiderTrades.com logo
Amy Simon net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Amy Simon Biography and Net Worth

Chief Medical Officer of Beam Therapeutics

Amy Simon, M.D. is Chief Medical Officer of Beam. Dr. Simon brings more than 20 years of clinical experience to Beam, serving in roles as a physician-scientist in academia and the biotechnology industry.

Dr. Simon joins Beam from Alnylam Pharmaceuticals, where she spent over a decade in various roles with increasing responsibility for the clinical development of RNAi-based medicines, most recently serving as Vice President, Clinical Development. During her tenure at Alnylam, she led the successful execution of clinical programs from natural history studies to Phase 1 through Phase 4 studies, regulatory interactions with both U.S. and ex-U.S. authorities, and drug approvals in the U.S. and EU. Dr. Simon was the lead clinician developing GIVLAARI® (givosiran) for patients with acute hepatic porphyria, which was approved by the Food and Drug Administration in 2019. Prior to entering the biotech industry, Dr. Simon worked in academia at Tufts University, serving as a professor and a director of the Asthma Center in the Pulmonary and Critical Care Division at Tufts University School of Medicine and as a professor at Tufts Graduate School of Biomedical Science where her laboratory conducted basic science research on asthma. She began her career in clinical practice, training as a resident in internal medicine and as a fellow in pulmonary and critical care medicine at Tufts Medical Center.

Dr. Simon holds a B.A. in History and Science from Harvard University, and an M.D. from Tufts University School of Medicine.

What is Amy Simon's net worth?

The estimated net worth of Amy Simon is at least $1.33 million as of July 1st, 2024. Dr. Simon owns 69,553 shares of Beam Therapeutics stock worth more than $1,330,549 as of April 22nd. This net worth evaluation does not reflect any other assets that Dr. Simon may own. Additionally, Dr. Simon receives a salary of $715,580.00 as Chief Medical Officer at Beam Therapeutics. Learn More about Amy Simon's net worth.

How old is Amy Simon?

Dr. Simon is currently 60 years old. There are 3 older executives and no younger executives at Beam Therapeutics. Learn More on Amy Simon's age.

What is Amy Simon's salary?

As the Chief Medical Officer of Beam Therapeutics Inc., Dr. Simon earns $715,580.00 per year. There are 2 executives that earn more than Dr. Simon. The highest earning executive at Beam Therapeutics is Mr. John M. Evans M.B.A., CEO & Director, who commands a salary of $1,130,000.00 per year. Learn More on Amy Simon's salary.

How do I contact Amy Simon?

The corporate mailing address for Dr. Simon and other Beam Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Beam Therapeutics can also be reached via phone at 857-327-8775 and via email at investors@beamtx.com. Learn More on Amy Simon's contact information.

Has Amy Simon been buying or selling shares of Beam Therapeutics?

Amy Simon has not been actively trading shares of Beam Therapeutics during the past quarter. Most recently, Amy Simon sold 502 shares of the business's stock in a transaction on Monday, July 1st. The shares were sold at an average price of $23.76, for a transaction totalling $11,927.52. Following the completion of the sale, the insider now directly owns 69,553 shares of the company's stock, valued at $1,652,579.28. Learn More on Amy Simon's trading history.

Who are Beam Therapeutics' active insiders?

Beam Therapeutics' insider roster includes Christine Bellon (Chief Legal Officer), Terry-Ann Burrell (CFO), Giuseppe Ciaramella (Insider), Graham Cooper (Director), John Evans (CEO), John Evans (CEO), and Amy Simon (Chief Medical Officer). Learn More on Beam Therapeutics' active insiders.

Are insiders buying or selling shares of Beam Therapeutics?

In the last twelve months, insiders at the sold shares 12 times. They sold a total of 298,408 shares worth more than $7,299,998.07. The most recent insider tranaction occured on April, 1st when insider Christine Bellon sold 5,674 shares worth more than $104,117.90. Insiders at Beam Therapeutics own 4.2% of the company. Learn More about insider trades at Beam Therapeutics.

Information on this page was last updated on 4/1/2025.

Amy Simon Insider Trading History at Beam Therapeutics

See Full Table

Amy Simon Buying and Selling Activity at Beam Therapeutics

This chart shows Amy Simon's buying and selling at Beam Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

Beam Therapeutics Company Overview

Beam Therapeutics logo
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $19.13
Low: $18.34
High: $19.31

50 Day Range

MA: $22.95
Low: $14.54
High: $34.16

2 Week Range

Now: $19.13
Low: $13.53
High: $35.25

Volume

1,977,010 shs

Average Volume

1,382,363 shs

Market Capitalization

$1.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02